Cardiogenic shock
1 paper
- Humans1
Trial sponsors
Central Hospital, Nancy, France
1 trialPhase 3164 people
Copenhagen University Hospital, Rigshospitalet
1 trialPhase 2100 people
1 trialPhase 250 people
1 trialPhase 246 people
Latest
5 in 12 monthsFrontiers in Pharmacology
Antecedent glucagon-like peptide-1 receptor agonist use and risk of sepsis-induced cardiomyopathy in type 2 diabetes: a United States real-world active-comparator cohort study
Cohort study of 189,156 peopleCardiomyopathy
AHA Scientific Sessions 2025 Abstract
Impact of Sodium Glucose Cotransporter 2-Inhibitors in Valvular Heart Disease
Study in peopleInterventions
AHA Scientific Sessions 2025 Abstract
Long-term Cardiovascular Outcomes and Predictors of Sodium Glucose Cotransporter 2 Inhibitor in Takotsubo Cardiomyopathy: A Propensity Matched National Analysis of The Trinetx Database
Study in peopleInterventions
AHA Scientific Sessions 2025 Abstract
Association of SGLT2 Inhibitor Use with Clinical Outcomes in Patients with Tricuspid Regurgitation in the Absence of Left Ventricular Systolic Dysfuncton: A Propensity Score-Matched Analysis
Study in peopleInterventions
AHA Scientific Sessions 2025 Abstract
Five-Year Outcomes of Glucagon-Like Peptide-1 Agonists in Obstructive Hypertrophic Cardiomyopathy: A Population-Based Retrospective Study
Study in peopleInterventions